Chimerix (CMRX) News Today $5.14 -0.03 (-0.48%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Wedbush Has Optimistic Outlook of Chimerix FY2025 EarningsChimerix, Inc. (NASDAQ:CMRX - Free Report) - Analysts at Wedbush upped their FY2025 earnings per share estimates for shares of Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will earn ($0.03) per shareFebruary 21 at 6:47 AM | marketbeat.comWedbush Has Positive Estimate for Chimerix FY2028 EarningsFebruary 21 at 3:31 AM | americanbankingnews.comChimerix: Potential 'First' In Targeting Recurrent High-Grade Glioma PatientsFebruary 20 at 7:51 PM | seekingalpha.comWhat is Wedbush's Forecast for Chimerix FY2028 Earnings?Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Analysts at Wedbush upped their FY2028 earnings estimates for Chimerix in a research report issued on Tuesday, February 18th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of $0.58 per share for tFebruary 20 at 7:42 AM | marketbeat.comWedbush Reiterates "Outperform" Rating for Chimerix (NASDAQ:CMRX)Wedbush reissued an "outperform" rating and set a $7.00 price target (up from $6.00) on shares of Chimerix in a research note on Tuesday.February 19 at 8:25 PM | marketbeat.comHC Wainwright Reaffirms Buy Rating for Chimerix (NASDAQ:CMRX)HC Wainwright reissued a "buy" rating and issued a $11.00 price target on shares of Chimerix in a report on Tuesday.February 19 at 4:09 PM | marketbeat.comChimerix's (CMRX) Buy Rating Reiterated at HC WainwrightFebruary 19 at 2:36 AM | americanbankingnews.comChimerix (NASDAQ:CMRX) Given "Outperform" Rating at WedbushWedbush reiterated an "outperform" rating and set a $7.00 target price (up previously from $6.00) on shares of Chimerix in a research note on Tuesday.February 19 at 1:49 AM | marketbeat.comChimerix stock rises on FDA priority review for dordaviproneFebruary 19 at 12:59 AM | au.investing.comChimerix Shares Touch 52-Week High on Speedy FDA Review of Brain Tumor TreatmentFebruary 19 at 12:59 AM | marketwatch.comChimerix’s NDA for dordaviprone accepted by FDAFebruary 19 at 12:59 AM | markets.businessinsider.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 18 at 4:01 PM | globenewswire.comValeo Financial Advisors LLC Buys 64,420 Shares of Chimerix, Inc. (NASDAQ:CMRX)Valeo Financial Advisors LLC grew its holdings in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 78.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 146,186 shares of the biopharmaceutical company's stock after purchasing an aFebruary 17, 2025 | marketbeat.comPalumbo Wealth Management LLC Buys New Position in Chimerix, Inc. (NASDAQ:CMRX)Palumbo Wealth Management LLC purchased a new position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 63,400 shares of the biopharmaceutical company's stock, valued at approxFebruary 16, 2025 | marketbeat.comInsider Selling: Chimerix, Inc. (NASDAQ:CMRX) CFO Sells 2,260 Shares of StockChimerix, Inc. (NASDAQ:CMRX - Get Free Report) CFO Michelle Laspaluto sold 2,260 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $4.51, for a total transaction of $10,192.60. Following the completion of the sale, the chief financial officer now directly owns 172,977 shares in the company, valued at approximately $780,126.27. This trade represents a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.February 15, 2025 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) Insider Sells $13,792.50 in StockChimerix, Inc. (NASDAQ:CMRX - Get Free Report) insider Allen S. Melemed sold 3,065 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.50, for a total transaction of $13,792.50. Following the completion of the transaction, the insider now owns 152,875 shares of the company's stock, valued at $687,937.50. This trade represents a 1.97 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.February 15, 2025 | marketbeat.comChimerix, Inc. (NASDAQ:CMRX) CEO Michael T. Andriole Sells 7,370 SharesChimerix, Inc. (NASDAQ:CMRX - Get Free Report) CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.February 15, 2025 | marketbeat.comMichelle Laspaluto Sells 2,260 Shares of Chimerix, Inc. (NASDAQ:CMRX) StockFebruary 15, 2025 | insidertrades.comChimerix SVP and general counsel sells $7,226 in stockFebruary 14, 2025 | msn.comChimerix CFO sells $10,195 in stock amid tax obligationFebruary 14, 2025 | msn.comChimerix, Inc. (NASDAQ:CMRX) Short Interest UpdateChimerix, Inc. (NASDAQ:CMRX - Get Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,570,000 shares, a growth of 66.0% from the January 15th total of 2,150,000 shares. Based on an average daily trading volume, of 4,390,000 shares, the short-interest ratio is presently 0.8 days. Approximately 4.5% of the company's stock are short sold.February 14, 2025 | marketbeat.com754,566 Shares in Chimerix, Inc. (NASDAQ:CMRX) Acquired by Peapod Lane Capital LLCPeapod Lane Capital LLC purchased a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 754,566 shares of the biopharmaceutical company's stock, valuedFebruary 13, 2025 | marketbeat.comChimerix stock soars to 52-week high, hits $4.3February 11, 2025 | msn.comInsider Selling: Chimerix, Inc. (NASDAQ:CMRX) VP Sells 2,800 Shares of StockFebruary 1, 2025 | insidertrades.comChimerix, Inc. (NASDAQ:CMRX) VP Sells $11,480.00 in StockChimerix, Inc. (NASDAQ:CMRX - Get Free Report) VP David Jakeman sold 2,800 shares of the company's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4.10, for a total value of $11,480.00. Following the completion of the sale, the vice president now owns 149,287 shares of the company's stock, valued at approximately $612,076.70. The trade was a 1.84 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.January 31, 2025 | marketbeat.comChimerix (NASDAQ:CMRX) Share Price Passes Above Two Hundred Day Moving Average - Here's WhyChimerix (NASDAQ:CMRX) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?January 30, 2025 | marketbeat.comChimerix to Present at JonesTrading Virtual Precision Medicine SymposiumJanuary 29, 2025 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 24, 2025 | globenewswire.comAssenagon Asset Management S.A. Has $2.85 Million Holdings in Chimerix, Inc. (NASDAQ:CMRX)Assenagon Asset Management S.A. boosted its stake in shares of Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 154.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 817,739 shares of the biopharmaceutical company'January 22, 2025 | marketbeat.comChimerix stock soars to 52-week high, hits $3.8January 21, 2025 | msn.comChimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short InterestChimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 1,810,000 shares, a drop of 47.4% from the December 15th total of 3,440,000 shares. Based on an average daily volume of 3,970,000 shares, the short-interest ratio is presently 0.5 days. Currently, 2.3% of the shares of the stock are sold short.January 14, 2025 | marketbeat.comChimerix to Speak Today at The White House Cancer Moonshot ForumJanuary 13, 2025 | markets.businessinsider.comChimerix (NASDAQ:CMRX) Share Price Crosses Above 50 Day Moving Average - Should You Sell?Chimerix (NASDAQ:CMRX) Stock Crosses Above 50-Day Moving Average - Here's What HappenedJanuary 7, 2025 | marketbeat.comChimerix Receives ‘Buy’ Rating from Edward White on Promising Drug Development and Strong Financial OutlookDecember 30, 2024 | markets.businessinsider.comA Glimpse Into The Expert Outlook On Chimerix Through 4 AnalystsDecember 30, 2024 | benzinga.comPromising Outlook for Chimerix: Strategic Developments and Financial Strength Justify Buy RatingDecember 30, 2024 | markets.businessinsider.comChimerix's (CMRX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $11.00 price target on shares of Chimerix in a research report on Monday.December 30, 2024 | marketbeat.comChimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaDecember 30, 2024 | globenewswire.comChimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short InterestChimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 647,700 shares, a drop of 8.8% from the November 15th total of 710,300 shares. Approximately 0.8% of the company's shares are sold short. Based on an average daily volume of 3,280,000 shares, the days-to-cover ratio is presently 0.2 days.December 16, 2024 | marketbeat.comWedbush Weighs in on Chimerix's Q4 Earnings (NASDAQ:CMRX)Chimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities researchers at Wedbush cut their Q4 2025 earnings estimates for shares of Chimerix in a research note issued to investors on Tuesday, December 10th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post eDecember 13, 2024 | marketbeat.comHC Wainwright Has Positive Forecast for Chimerix Q4 EarningsChimerix, Inc. (NASDAQ:CMRX - Free Report) - Equities research analysts at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for shares of Chimerix in a research report issued on Wednesday, December 11th. HC Wainwright analyst E. White now forecasts that the biopharmaceuticDecember 13, 2024 | marketbeat.comWedbush Has Negative Outlook for Chimerix Q2 EarningsChimerix, Inc. (NASDAQ:CMRX - Free Report) - Stock analysts at Wedbush reduced their Q2 2025 EPS estimates for Chimerix in a research note issued to investors on Monday, December 9th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will post earnings of ($0.27)December 12, 2024 | marketbeat.comEdward White’s Buy Rating on Chimerix Driven by Promising Clinical Data and Strategic NDA PlansDecember 11, 2024 | markets.businessinsider.comInvestors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's PremarketDecember 10, 2024 | msn.comSmall Cap Soars On FDA Submission PlansDecember 10, 2024 | theglobeandmail.comTD Cowen Reaffirms Their Buy Rating on Chimerix (CMRX)December 10, 2024 | markets.businessinsider.comChimerix Soars 220% on FDA Filing Plans for Lifesaving Brain Cancer TherapyDecember 10, 2024 | finance.yahoo.comChimerix Stock Draws Heavy Retail Chatter After Landing Price-Target Hike On FDA Submission Plan For Cancer DrugDecember 10, 2024 | msn.comChimerix to submit dordaviprone NDA to FDA, seeks accelerated approvalDecember 9, 2024 | markets.businessinsider.comChimerix Shares Top 52-week Highs, Company Plans FDA Submission of Cancer Drug DordaviproneDecember 9, 2024 | marketwatch.com Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Media Mentions By Week CMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMRX News Sentiment▼0.600.60▲Average Medical News Sentiment CMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMRX Articles This Week▼332▲CMRX Articles Average Week Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcutis Biotherapeutics News Today Amphastar Pharmaceuticals News Today Immunocore News Today Kiniksa Pharmaceuticals News Today Dyne Therapeutics News Today Structure Therapeutics News Today Ardelyx News Today Indivior News Today Nurix Therapeutics News Today Vir Biotechnology News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMRX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
